Suspension of trading
Acorda Therapeutics Stock OTC Markets
Stocks
ACOR
US00484M7002
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-10.00% | -99.91% |
| 24-08-13 | First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc. | CI |
| 24-08-07 | Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc. | CI |
| 1 week | -10.00% | ||
| 1 month | -87.85% | ||
| 3 months | -98.41% | ||
| 6 months | -99.90% | ||
| Current year | -99.91% |
| 1 week | 0 |  | 0.02 |
| 1 month | 0 | | 0.15 |
| 3 years | 0 | | 99.8 |
| 5 years | 0 | | 535.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sofia Ali
COO | Chief Operating Officer | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -10.00% | -99.92% | -99.98% | 16.77K | |
| -4.14% | -8.06% | +57.35% | +117.24% | 56.98B | |
| +1.84% | +1.65% | +76.90% | +95.68% | 53.58B | |
| -3.02% | +2.99% | +18.85% | +463.14% | 25.63B | |
| -1.48% | -2.41% | -19.53% | -14.67% | 23.51B | |
| +2.43% | +5.86% | +46.56% | +0.42% | 19.43B | |
| -3.19% | 0.00% | +33.99% | -26.87% | 18.12B | |
| -6.84% | +2.18% | +203.03% | +348.11% | 16.46B | |
| +8.74% | +10.46% | +47.66% | - | 14.13B | |
| -0.85% | +2.16% | +25.59% | +197.48% | 14.35B | |
| Average | -0.77% | +1.16% | +39.05% | +120.06% | 26.91B | |
| Weighted average by Cap. | -1.11% | +0.29% | +54.98% | +137.75% |
Employees
-
- Stock Market
- Stocks
- ACOR.Q Stock
- ACOR Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
